President launches India's first homegrown CAR T-cell therapy for cancer treatment, calls it 'new hope'

Developed by the IIT Bombay and the Tata Memorial Centre, this gene-based therapy will help in curing different types of cancer

Updated - April 04, 2024 06:22 pm IST

Published - April 04, 2024 05:26 pm IST - Mumbai

President Droupadi Murmu with Maharashtra Governor Ramesh Bais, IIT Bombay Director Subhasis Chaudhuri, Tata Memorial Centre Director Sudeep Gupta and others during the launch of the first indigenous CAR-T cell therapy, in Mumbai on April 4, 2024.

President Droupadi Murmu with Maharashtra Governor Ramesh Bais, IIT Bombay Director Subhasis Chaudhuri, Tata Memorial Centre Director Sudeep Gupta and others during the launch of the first indigenous CAR-T cell therapy, in Mumbai on April 4, 2024. | Photo Credit: PTI

President Droupadi Murmu on April 4 launched India’s first indigenously-developed CAR T-cell therapy for treatment of cancer, hailing it as a “major breakthrough” that provides a “new hope for the humankind” in the battle against the disease.

During the launch event held at the Indian Institute of Technology (IIT) Bombay located in Powai in Mumbai, she also said the development of this therapy is an example of the ‘Make in India’ initiative.

Developed by the IIT Bombay and the Tata Memorial Centre, this gene-based therapy will help in curing different types of cancer. This NexCAR19 CAR T-cell therapy is the country’s first ‘Made in India’ CAR T-cell therapy, which will significantly bring down the cost of cancer treatment.

Also read: Indian-origin teen first to get U.K.’s life-changing cancer treatment

Speaking on the occasion, President Murmu said the CAR T-cell therapy is considered as one of the phenomenal advances in medical sciences.

“The development of this therapy is also an example of the ‘Make in India’ initiative and speaks volume about Indian scientists and physicians,” she said.

“The launch of India’s first gene therapy is a major breakthrough in our battle against cancer. As this line of treatment, named CAR T-cell therapy, is accessible and affordable, it provides a new hope for the whole of humankind,” she said.

Sudeep Gupta, Director of the Tata Memorial Centre, said the CAR T-cell therapy has been an enormously expensive treatment which is out of the reach of an overwhelming majority of people.

“NexCAR19 has been rolled out at approximately one-tenth of the price at which it is available outside India,” he said.

IIT Bombay Director Prof. Subhasis Chaudhuri said the treatment costs approximately ₹4 crore abroad.

The low-cost CAR T-cell therapy is a huge achievement for our country and for cancer patients in India, and it places India firmly on the global map of cell and gene therapy, he said.

Mr. Gupta said the creation and rollout of NexCAR19 is a historic milestone in the field of cancer care and genetic engineering.

“This treatment is not only a scientific achievement of the highest order, but also has immense practical application. NexCAR19 will save many, many lives and wipe many, many tears,” he said.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.